ロード中...
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma
PURPOSE: This phase I trial was performed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), preliminary efficacy, and pharmacokinetics (PK) of LY01610, a novel liposome-encapsulated irinotecan, in patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS...
保存先:
| 出版年: | Cancer Chemother Pharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8143070/ https://ncbi.nlm.nih.gov/pubmed/34031756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04294-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|